RenovoRx rises on positive late-stage trial data for pancreatic cancer therapy

RenovoRx

30/03/2023 15:11

** Biopharma co RenovoRx Inc's shares  RNXT.O  rise 16.4% to
$4.5
    ** Co reports new positive data from late-stage trials's
interim analysis for its therapy, RenovoGem, in pancreatic
cancer treatment
    ** Says trial's early analysis shows the therapy enhances
patient survival; showed 60% improvement in patients vs the
study control arm and current standard of care 
    ** RenovoGem is RNXT's first drug-device combination product
candidate that utilizes company's therapy platform to deliver an
FDA-approved systemic chemotherapy
    ** Systemic chemotherapy uses anti-cancer drugs that are
injected into a vein or given by mouth
    ** Adds patients also had greater than 65% reduction in
adverse events, that can include nausea, fatigue, and a decline
in white blood cells vs systemic chemotherapy
    ** Co's stock up 89.4% YTD 

 (Reporting by Pratik Jain in Bengaluru)
 ((Pratik.Jain@thomsonreuters.com;))